Results 71 to 80 of about 9,493 (159)

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment

Blood Advances
: In patients with paroxysmal nocturnal hemoglobinuria (PNH), the complement component 5 (C5) inhibitors ravulizumab and eculizumab control terminal complement activity and intravascular hemolysis, which are drivers of morbidity and mortality.
Austin G. Kulasekararaj, Jong Wook Lee, Christopher J. Patriquin, Caroline I. Piatek, Alexander Röth, Wilma Barcellini, Robert A. Brodsky, Jun-ichi Nishimura, Ji Yu, Mohammed Mahdi, Régis Peffault de Latour   +10 more
doaj   +1 more source

Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

Case Reports in Nephrology, 2016
In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements.
Camino García Monteavaro, Carmen Peralta Roselló, Borja Quiroga, José María Baltar Martín, Lorena Castillo Eraso, Fernando de Álvaro Moreno, Alberto Martínez Vea, María Teresa Visus-Fernández de Manzanos   +7 more
doaj   +1 more source

Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria

Haematologica, 2007
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis leading to anemia and other clinical manifestations. Transfusions are often required to support hemoglobin at tolerable levels.
A. Hill, S.J. Richards, R.P. Rother, P. Hillmen   +3 more
doaj   +1 more source

Safety and Effectiveness of Eculizumab throughout Three Pregnancies in a Patient with Refractory Generalized Myasthenia Gravis: A Case Report

Case Reports in Neurology
We describe maternal and fetal outcomes in a patient who had three successful pregnancies while being treated with eculizumab for AChR+ gMG.
Nadia Khalil, Claudia Guerra Hernandez, Jerrica Farias, Kathleen Murray, Niraja Suresh, Clifton Gooch, Tuan H. Vu   +6 more
doaj   +1 more source

Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report

Frontiers in Pediatrics
Eculizumab, a recombined humanized monoclonal antibody which possesses high affinity for the complement protein C5, is a therapeutic agent utilized in the treatment of atypical hemolytic uremic syndrome (aHUS) by inhibiting the terminal complement ...
Xin Wei, Xinzhu Liu, Yingying Yu, Wei Xie, Wentao Luo, Ye Tu, Shuhong Bu, Guimei Guo   +7 more
doaj   +1 more source

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation

Case Reports in Transplantation, 2017
Thrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi) kidney transplantation (KT). Herein, we report on two cases of ABMR with biological and histological features of thrombotic
Luca Lanfranco, Melanie Joly, Arnaud Del Bello, Laure Esposito, Noelle Cognard, Peggy Perrin, Bruno Moulin, Nassim Kamar, Sophie Caillard   +8 more
doaj   +1 more source

Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

Advances in Hematology, 2014
Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy
Han-Mou Tsai, Elizabeth Kuo
doaj   +1 more source

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria

Therapeutic Advances in Hematology, 2019
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration ...
Robert M. Stern, Nathan T. Connell
doaj   +1 more source

Differential complement activation by alloantibodies in sickle cell hyperhaemolysis syndrome may influence disease course

British Journal of Haematology, Volume 208, Issue 6, Page 2311-2314, June 2026.
Mamie M. Thant, Jahnavi Gollamudi, Stefanie W. Benoit, Satheesh Chonat, Jose A. Cancelas   +4 more
wiley   +1 more source